ROCKVILLE, Md. — For the parents of an infant suffering from unexplained seizures, the "diagnostic odyssey"—a period often characterized by months or years of fragmented testing, uncertainty, and trial-and-error medication—can be a harrowing experience. However, a landmark international study unveiled on October 22, 2026, by the American Society of Human Genetics (ASHG) suggests that this protracted process may soon become a relic of the past.
The Gene-STEPS study, a comprehensive prospective analysis of 515 infants, has demonstrated that rapid genome sequencing (RGS) can deliver a definitive genetic diagnosis for nearly half of all infants presenting with new-onset epilepsy. By moving genetic testing to the forefront of the diagnostic pathway, clinicians may finally be able to transition from reactive care to proactive, precision-guided medicine.
The Core Findings: A New Diagnostic Gold Standard
The Gene-STEPS study represents one of the largest and most diverse investigations into the genetic architecture of infantile-onset epilepsy. Led by Dr. Gregory Costain, the study focused on 515 infants under the age of 12 months who presented with either new-onset epilepsy or complex febrile seizures of unknown origin.
The results were striking: researchers were able to provide a genetic diagnosis for 228 of the 515 participants—a success rate of 44%. This was achieved within an accelerated timeframe, with clinically accredited laboratories returning results in an average of just three weeks.
The study identified genomic variants across 111 distinct genes or genomic regions, underscoring the profound genetic heterogeneity that characterizes infantile epilepsy. While the diagnostic landscape is vast, five specific genes—PRRT2, SCN1A, KCNQ2, SCN8A, and SCN2A—accounted for 37% of all identified cases. However, the study also revealed the rarity of many conditions, with 82 unique diagnoses found in only a single infant each, illustrating why a broad genomic approach is superior to traditional, single-gene testing methods.
A Chronology of the Diagnostic Odyssey
To understand the significance of the Gene-STEPS study, one must look at the traditional path of a pediatric epilepsy patient. Historically, infants with seizures undergo a battery of metabolic, neurological, and imaging tests. Genetic testing, if performed at all, often occurred in a piecemeal fashion—testing one gene at a time based on a clinical hunch.
The Timeline of Traditional Care
- Symptom Onset: An infant experiences their first seizure.
- Initial Stabilization: Emergency care focuses on stopping the seizure; underlying causes remain elusive.
- The "Wait and See" Approach: Many physicians rely on broad-spectrum anti-seizure medications that may be ineffective or even harmful depending on the underlying genetic mutation.
- Fragmented Testing: Months pass as metabolic panels, EEGs, and MRI scans are ordered, often yielding normal results despite a clear genetic pathology.
- Delayed Diagnosis: Genetic testing is finally ordered as a "last resort," often after the window for early intervention has narrowed.
The Gene-STEPS Paradigm
The Gene-STEPS study proposes a "first-line" approach. By integrating rapid genome sequencing at the onset of symptoms, the study demonstrated that clinicians could bypass the diagnostic odyssey entirely. With results returned within three weeks, medical teams are empowered to move from a generic treatment plan to a genotype-specific one almost immediately.
Supporting Data: The Power of Precision
The implications of the Gene-STEPS data extend far beyond simply "naming" the disease. For more than half of the infants who received a diagnosis, the information directly influenced their clinical management.
Impact on Clinical Decision-Making
- Tailored Therapies: Many genetic epilepsies respond differently to standard anti-seizure medications. Some common drugs can actually exacerbate seizures in patients with specific genetic mutations. Knowing the mutation allows clinicians to avoid contraindicated drugs.
- Surveillance Protocols: Certain genetic epilepsy syndromes come with comorbid risks, such as developmental delays, cardiac arrhythmias, or immunological issues. A diagnosis allows for proactive screening for these secondary conditions.
- Emerging Therapeutics: The study found that 16% of the diagnoses were potentially amenable to antisense oligonucleotide (ASO) therapies. These cutting-edge treatments act on the genetic level to alter RNA activity, offering a potential "cure" or significant symptom modification rather than mere seizure suppression.
Technological Advancements
The study’s success was bolstered by the use of advanced sequencing methods. While standard RGS identified many cases, researchers employed RNA sequencing and long-read genome sequencing to resolve cases that remained elusive under traditional short-read technology. This combination of techniques highlights the importance of keeping pace with the rapid evolution of genomic tools in clinical settings.
Official Responses and Expert Commentary
Dr. Gregory Costain, speaking on behalf of the Gene-STEPS consortium, emphasized that the study is a call to action for healthcare systems worldwide. "The current approach to infantile epilepsy is often slow and fragmented," Dr. Costain noted. "Our data confirms that rapid genome sequencing is not just an elective tool; it is a clinical necessity that changes the trajectory of care for infants and their families."
The American Society of Human Genetics (ASHG), which facilitated the dissemination of these findings, has long championed the integration of genomics into standard practice. Representatives from ASHG noted that the Gene-STEPS study provides the high-level evidence required by insurance providers and policymakers to justify covering rapid sequencing as a standard-of-care procedure.
By demonstrating that 44% of cases can be solved, the study removes the primary argument against universal sequencing: that it is a "fishing expedition" with low yield. Instead, the study establishes that for infants with unexplained seizures, the genetic cause is the primary suspect and should be treated as such.
Clinical and Socioeconomic Implications
The transition to first-line rapid genome sequencing carries significant implications for the healthcare landscape:
1. Reduction of Healthcare Costs
While the upfront cost of genome sequencing is higher than traditional blood panels, the long-term economic benefits are substantial. By avoiding years of ineffective medications, redundant diagnostic imaging, and unnecessary hospitalizations, the healthcare system stands to save significant resources.
2. Family Planning and Genetic Counseling
A definitive diagnosis provides parents with clarity, allowing them to access appropriate support networks and make informed decisions regarding future family planning. It replaces the guilt and confusion of the "unknown" with actionable medical data.
3. The Future of Therapeutic Development
By identifying the specific gene mutations responsible for epilepsy in a large cohort, the Gene-STEPS study provides a roadmap for pharmaceutical companies. The concentration of 37% of diagnoses into just five genes provides a clear, high-priority target for drug development. If treatments for these five genes are perfected, the impact on pediatric epilepsy prevalence could be transformative.
Conclusion: A New Frontier in Pediatric Neurology
The Gene-STEPS study is more than just a collection of data; it is a roadmap for the future of pediatric neurology. By proving that 44% of infant epilepsy cases have a clear, actionable genetic root, the study shifts the burden of proof. It is no longer a question of if we should perform genetic testing on these infants, but how quickly we can ensure it is available to every child regardless of their geography or socioeconomic status.
As the findings from the Gene-STEPS study are disseminated into clinical practice, the medical community stands at a turning point. With the integration of RNA sequencing, long-read technology, and early genomic intervention, the "diagnostic odyssey" is finally coming to an end, replaced by a new era of precision medicine that prioritizes the infant’s future health and development from the very first day of care.
About the American Society of Human Genetics (ASHG)
The American Society of Human Genetics (ASHG) is the leading global organization advancing the science of human genetics and genomics. Representing nearly 8,000 researchers, clinicians, genetic counselors, educators, and other professionals, ASHG drives progress in understanding the human genome and its role in health and disease. For more information, visit www.ashg.org.
About the Author
